41 completed, 6 terminated, 5 unknown, 3 active not recruiting. 59 Phase 1, 19 Phase 2.
Follow aflibercept: new trials by email Literature Review of aflibercept trials Research Report on aflibercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD SCT520FF, EYLEA 2 MG - nAMD | Phase 1 / Phase 2 | Recruiting | Sinocelltech Ltd. | 82 | 2024-11-26 | 2025-09-04 |
| A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) Aflibercept (2.0 mg) - Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD) | Phase 1 | Active not recruiting | Exegenesis Bio | 12 | 2024-09-10 | 2026-04-08 |
| Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration CG-P5 peptide, Placebo, Aflibercept Injection [Eylea] - Age-related Wet Macular Degeneration | Phase 1 | Recruiting | Caregen Co. Ltd. | 45 | 2023-12-22 | 2025-02-07 |
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant - Neovascular Age-related Macular Degeneration (nAMD) | Phase 1 / Phase 2 | Active not recruiting | Alcon Research | 139 | 2023-12-06 | 2026-08-27 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema RO7446603, Aflibercept, Faricimab - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Genentech, Inc. | 388 | 2022-06-22 | 2026-06-23 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration SCB-420, Aflibercept - Wet Age-related Macular Degeneration | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2022-04-01 | 2022-04-19 | |
| Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration OTX-TKI/Sham, Aflibercept/Sham - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Ocular Therapeutix, Inc. | 21 | 2021-07-28 | 2024-01-26 |
| Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema 9MW0813, Aflibercept - Diabetic Macular Edema | Phase 1 | Completed | Mabwell (Shanghai) Bioscience Co., Ltd. | 24 | 2021-02-26 | 2022-04-12 |
| Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD CLS-AX, Anti-VEGF - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 27 | 2020-12-15 | 2023-09-18 |
| Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients IBI302 (the first dose level), IBI302 (the second dose level), Aflibercept - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 18 | 2020-05-28 | 2021-11-11 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD Eylea, ALT-L9 - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Alteogen, Inc. | 28 | 2020-02-05 | 2022-01-20 |
| Use of Ziv Aflibercept in Different Retinal Diseases Ziv-Aflibercept 25 MG/ML [Zaltrap] - Central Retinal Vein Occlusion With Macular Edema | Phase 1 / Phase 2 | Completed | Amin El Sayed Nawar | 55 | 2019-06-01 | 2021-10-11 |
| Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept Aflibercept - Irvine-Gass Syndrome | Phase 1 | Terminated | Tufts Medical Center | 1 | 2019-02-22 | 2024-10-15 |
| CLN-0046: Treatment of AMD Subjects With OTX-TKI OTX-TKI, Anti-VEGF - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Ocular Therapeutix, Inc. | 29 | 2019-02-18 | 2024-07-10 |
| AAVCAGsCD59 for the Treatment of Wet AMD Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral prednisolone - Wet Age-related Macular Degeneration | Phase 1 | Completed | Janssen Research & Development, LLC | 25 | 2018-09-13 | 2025-03-30 |
| Intense Treatment Regimen With Intravitreal Aflibercept Injection Aflibercept Injection - Neovascular Age-Related Macular Degeneration | Phase 1 / Phase 2 | Unknown | Vitreous -Retina- Macula Consultants of New York | 30 | 2018-09-11 | 2019-01-10 |
| A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Aflibercept, OPT-302, Sham intravitreal injection - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Opthea Limited | 153 | 2018-01-16 | 2025-04-22 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
Showing 20 of 59. Sign in to see all of them.
Neoplasms (8) · Macular Degeneration (7) · Colorectal Neoplasms (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Mantle-Cell (4) · Neoplasm Metastasis (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Sarcoma (4) · Carcinoma, Ovarian Epithelial (3)
Regeneron Pharmaceuticals (10) · Sanofi (8) · National Cancer Institute (NCI) (6) · Clearside Biomedical, Inc. (2) · Ocular Therapeutix, Inc. (2) · Alcon Research (1) · Alteogen, Inc. (1) · Amin El Sayed Nawar (1) · Arshad Khanani (1) · Balamurali Ambati (1) · California Retina Consultants (1) · Caregen Co. Ltd. (1) · Clover Biopharmaceuticals AUS Pty (1) · Exegenesis Bio (1) · Genentech, Inc. (1)
United States (41) · China (6) · Canada (3) · Japan (3) · Australia (2) · Belgium (2) · Israel (2) · Italy (2) · Denmark (1) · Egypt (1) · France (1) · Germany (1) · Latvia (1) · Lebanon (1) · Puerto Rico (1)
Avner Ingerman, MD (3) · Jakob Dupont, MD (2) · William P. Tew, MD (2) · Ahmad Mansour, MD (1) · Alain Hendlisz, MD (1) · Alice P Chen, M.D. (1) · Arshad M Khanani, MD (1) · Aung Naing (1) · Balamurali Ambati, M.D., Ph.D., M.B.A. (1) · Charles P. Semba, MD (1) · Corinne Haioun, MD (1) · Dennis M Marcus, MD (1)
PMID 19949018, PMID 20028764, PMID 22002018, PMID 16234465, PMID 19549103, PMID 19936307, PMID 20136420, PMID 21546089, PMID 21992853, PMID 22775078, PMID 22805331, PMID 23179335, PMID 23429593, PMID 24292447, PMID 25001321, PMID 25531046, PMID 25677668, PMID 26114826, PMID 27020759, PMID 27124775, PMID 29853657, PMID 31675952, PMID 32631787, PMID 33076864, PMID 35264434, PMID 35768859, PMID 35771301, PMID 36410472, PMID 38236249, PMID 39207600
P30CA016672 (1), P50CA083639 (1), U01CA062461 (1), U01CA062490 (1), U01CA097452 (1), U01CA137443 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186709 (1)